

John M. Lambert, Ph.D.

Consultant/Scientific Advisor

Honorary Professor, The Queen's University Belfast, Northern Ireland, UK.

Short Biography

Dr. Lambert graduated from Christ's College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then earned a Ph.D. in Biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham.

Dr Lambert's postdoctoral training was at the University of California, Davis (1976 – 1980), working on ribosome structure in the laboratory of Dr Robert R. Traut, and at the University of Glasgow, Scotland, UK (1980 – 1982), working on the *arom* multienzyme complex in the laboratory of Dr John R. Coggins.

In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, Boston, as the second scientist recruited to work on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics.

Dr. Lambert joined ImmunoGen in 1987 when the Company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the Company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the Company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016.

During Dr Lambert's tenure in leadership roles at ImmunoGen, scientists at the Company invented the ADC technology that ultimately resulted in the Genentech/Roche drug, KADCYLA® (approved in 2013 for treating HER2+ breast cancer), discovered the anti-CD38 antibody that became the Sanofi drug SARCLISA®, and created several other ADC molecules that were taken into clinical development. One of these ADCs is ImmunoGen's drug ELAHERE® that received accelerated approval from FDA in November 14, 2022, for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer, and which was converted to full approval on March 22, 2024 (ImmunoGen was acquired by AbbVie in February 2024).

Since January, 2018, Dr Lambert consults with and/or advises a number of start-up and early-stage Biopharma companies and VC firms on ADC research, ADC technologies, ADC programs and ADC development.

Dr Lambert is the author/co-author of over 125 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed to an Honorary Professorship at The Queen's University Belfast, Northern Ireland, UK.

John M. Lambert, Ph.D.

Consultant/Scientific Advisor

19 Chalk Street

Cambridge, MA 02139, USA.

TEL: +1 617-710-5188

EMAIL: attagerconsulting@gmail.com